The investigational parathyroid-hormone–related protein (PTHrP) analog abaloparatide (Radius Health) significantly reduced fractures in high-risk postmenopausal women with osteoporosis, a key phase 3 study has shown. Findings from the 18-month randomized, double-blind placebo-controlled Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial of more than 2000 women were presented March 5 here at the annual meeting of the Endocrine Society, ENDO 2015, by Paul Miller, MD, of the Colorado Center for Bone Research, Lakewood.
Abaloparatide was associated with an 86% reduction in vertebral fracture incidence — the primary end point — compared with placebo. While that effect was similar to the 80% reduction in vertebral-fracture rate seen with the currently available osteoanabolic PTHrP analog teriparatide (Forteo, Eli Lilly), abaloparatide produced significantly greater…
